Answers are grounded in this paper and cite their sources.
The running cost for clinical cancer treatment has risen dramatically. It is a huge burden to government fiscal budgets and cancer patients’ medical expenditure. Previously, we often create new drug and methodology of high cost and waste human resources for development of many less effects and expensive anticancer drugs or other sophisticated methodologies. These efforts will greatly increase therapeutic costs. Now some countries, such as USA or Japan, are overburden with high expense of medical resources in human
No takes yet. Share an insight, caveat, or question.
Da-Yong Lu Ting-Ren Lu (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: